Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Sepsis Trial Prompts Biotech-Style Jump In Second Quarter

Executive Summary

Wall Street's enthusiastic response to Lilly's potential sepsis therapy may represent the triumph of biotechnology - at least in terms of investor approaches to pharmaceutical stock valuations.

You may also be interested in...



Lilly, Barr Expect Prozac Generics In August 2001 After Appeals Court Ruling

Lilly and Barr expect generic competition to Prozac to arrive in August 2001 after an Aug. 9 Washington D.C. federal appeals court decision in favor of Barr's challenge of a fluoxetine patent.

Lilly, Barr Expect Prozac Generics In August 2001 After Appeals Court Ruling

Lilly and Barr expect generic competition to Prozac to arrive in August 2001 after an Aug. 9 Washington D.C. federal appeals court decision in favor of Barr's challenge of a fluoxetine patent.

Lilly Zyprexa IM Launch Planned For 2001; 2Q Sales Top $550 Mil.

Lilly hopes to introduce an intramuscular formulation of the antipsychotic Zyprexa by mid-2001.

Related Content

UsernamePublicRestriction

Register

PS036305

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel